Comparative efficacy of tocilizumab, abatacept and rituximab after non‐TNF inhibitor failure: results from a multicentre study
Identifieur interne : 001D87 ( Main/Exploration ); précédent : 001D86; suivant : 001D88Comparative efficacy of tocilizumab, abatacept and rituximab after non‐TNF inhibitor failure: results from a multicentre study
Auteurs : Tristan Pascart [France, Niger] ; Peggy Philippe [France] ; Elodie Drumez [France] ; Xavier Deprez [France] ; Bernard Cortet [France] ; Alain Duhamel [France] ; Eric Houvenagel [France] ; René-Marc Flipo [France]Source :
- International Journal of Rheumatic Diseases [ 1756-1841 ] ; 2016-11.
Descripteurs français
- KwdFr :
- Abatacept (effets indésirables), Abatacept (usage thérapeutique), Adulte d'âge moyen, Anticorps monoclonaux humanisés (effets indésirables), Anticorps monoclonaux humanisés (usage thérapeutique), Antirhumatismaux (effets indésirables), Antirhumatismaux (usage thérapeutique), Facteurs temps, Femelle, France, Humains, Indice de gravité médicale, Marqueurs biologiques (sang), Mâle, Polyarthrite rhumatoïde (diagnostic), Polyarthrite rhumatoïde (immunologie), Polyarthrite rhumatoïde (sang), Polyarthrite rhumatoïde (traitement médicamenteux), Produits biologiques (effets indésirables), Produits biologiques (usage thérapeutique), Protéine C-réactive (métabolisme), Rituximab (effets indésirables), Rituximab (usage thérapeutique), Substitution de médicament, Sujet âgé, Sédimentation du sang, Échec thérapeutique, Études rétrospectives.
- MESH :
- diagnostic : Polyarthrite rhumatoïde.
- effets indésirables : Abatacept, Anticorps monoclonaux humanisés, Antirhumatismaux, Produits biologiques, Rituximab.
- immunologie : Polyarthrite rhumatoïde.
- métabolisme : Protéine C-réactive.
- sang : Marqueurs biologiques, Polyarthrite rhumatoïde.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- usage thérapeutique : Abatacept, Anticorps monoclonaux humanisés, Antirhumatismaux, Produits biologiques, Rituximab.
- Adulte d'âge moyen, Facteurs temps, Femelle, France, Humains, Indice de gravité médicale, Mâle, Substitution de médicament, Sujet âgé, Sédimentation du sang, Échec thérapeutique, Études rétrospectives.
English descriptors
- KwdEn :
- Abatacept (adverse effects), Abatacept (therapeutic use), Aged, Antibodies, Monoclonal, Humanized (adverse effects), Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (adverse effects), Antirheumatic Agents (therapeutic use), Arthritis, Rheumatoid (blood), Arthritis, Rheumatoid (diagnosis), Arthritis, Rheumatoid (drug therapy), Arthritis, Rheumatoid (immunology), Biological Products (adverse effects), Biological Products (therapeutic use), Biomarkers (blood), Blood Sedimentation, C-Reactive Protein (metabolism), Drug Substitution, Female, France, Humans, Male, Middle Aged, Retrospective Studies, Rituximab (adverse effects), Rituximab (therapeutic use), Severity of Illness Index, Time Factors, Treatment Failure.
- MESH :
- chemical , adverse effects : Abatacept, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Biological Products, Rituximab.
- chemical , blood : Biomarkers.
- chemical , metabolism : C-Reactive Protein.
- chemical , therapeutic use : Abatacept, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Biological Products, Rituximab.
- blood : Arthritis, Rheumatoid.
- diagnosis : Arthritis, Rheumatoid.
- drug therapy : Arthritis, Rheumatoid.
- immunology : Arthritis, Rheumatoid.
- Aged, Blood Sedimentation, Drug Substitution, Female, France, Humans, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment Failure.
Abstract
Aims: The aim of this study was to compare the efficacy of tocilizumab, rituximab and abatacept after a non‐tumor necrosis factor inhibitor (non‐TNFi) failure for the treatment of rheumatoid arthritis (RA). Materials and methods: This retrospective multi‐centre study included patients treated for RA with abatacept, rituximab or tocilizumab after having received in the previous line the first non‐TNFi. Data were collected from patient charts. The primary endpoint was the delta Disease Activity Index of 28 joints – erythrocyte sedimentation rate (DAS28‐ESR) and DAS28‐CRP (C‐reactive protein) at 12 months. The relative change in primary outcome measures from baseline were calculated. Results: One hundred patients started a second non‐TNFi between 2006 and 2013, including 15 patients treated with rituximab, 36 with tocilizumab and 49 with abatacept. The change of DAS28‐ESR was significantly different between the three groups (P = 0.001). In post hoc pairwise comparisons, patients treated with tocilizumab had a higher decrease of the DAS28‐ESR than patients treated by abatacept (median [interquartile range: IQR]: 36% [0; 54%] vs. 0% [0; 20%], P = 0.002). A similar non‐significant difference was found between tocilizumab and rituximab (median [IQR] decrease: 36% [0; 54%] vs. 0% [−11; 34%], P = 0.07). Similar results were found with the 12 months change in DAS28‐CRP. Conclusions: This study suggests a better efficacy of tocilizumab compared with abatacept and rituximab in situations of non‐TNFi failure.
Url:
DOI: 10.1111/1756-185X.12845
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000038
- to stream Istex, to step Curation: 000038
- to stream Istex, to step Checkpoint: 000094
- to stream PubMed, to step Corpus: 000F05
- to stream PubMed, to step Curation: 000F05
- to stream PubMed, to step Checkpoint: 000E98
- to stream Ncbi, to step Merge: 001118
- to stream Ncbi, to step Curation: 001118
- to stream Ncbi, to step Checkpoint: 001118
- to stream Main, to step Merge: 001D87
- to stream Main, to step Curation: 001D87
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparative efficacy of tocilizumab, abatacept and rituximab after non‐TNF inhibitor failure: results from a multicentre study</title><author><name sortKey="Pascart, Tristan" sort="Pascart, Tristan" uniqKey="Pascart T" first="Tristan" last="Pascart">Tristan Pascart</name></author><author><name sortKey="Philippe, Peggy" sort="Philippe, Peggy" uniqKey="Philippe P" first="Peggy" last="Philippe">Peggy Philippe</name></author><author><name sortKey="Drumez, Elodie" sort="Drumez, Elodie" uniqKey="Drumez E" first="Elodie" last="Drumez">Elodie Drumez</name></author><author><name sortKey="Deprez, Xavier" sort="Deprez, Xavier" uniqKey="Deprez X" first="Xavier" last="Deprez">Xavier Deprez</name></author><author><name sortKey="Cortet, Bernard" sort="Cortet, Bernard" uniqKey="Cortet B" first="Bernard" last="Cortet">Bernard Cortet</name></author><author><name sortKey="Duhamel, Alain" sort="Duhamel, Alain" uniqKey="Duhamel A" first="Alain" last="Duhamel">Alain Duhamel</name></author><author><name sortKey="Houvenagel, Eric" sort="Houvenagel, Eric" uniqKey="Houvenagel E" first="Eric" last="Houvenagel">Eric Houvenagel</name></author><author><name sortKey="Flipo, Rene Arc" sort="Flipo, Rene Arc" uniqKey="Flipo R" first="René-Marc" last="Flipo">René-Marc Flipo</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D3B23ACDCB126D11E04A087E0FB69A6B2A03E277</idno><date when="2016" year="2016">2016</date><idno type="doi">10.1111/1756-185X.12845</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-S74HBQC2-P/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000038</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000038</idno><idno type="wicri:Area/Istex/Curation">000038</idno><idno type="wicri:Area/Istex/Checkpoint">000094</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000094</idno><idno type="wicri:doubleKey">1756-1841:2016:Pascart T:comparative:efficacy:of</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:27018857</idno><idno type="wicri:Area/PubMed/Corpus">000F05</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F05</idno><idno type="wicri:Area/PubMed/Curation">000F05</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F05</idno><idno type="wicri:Area/PubMed/Checkpoint">000E98</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E98</idno><idno type="wicri:Area/Ncbi/Merge">001118</idno><idno type="wicri:Area/Ncbi/Curation">001118</idno><idno type="wicri:Area/Ncbi/Checkpoint">001118</idno><idno type="wicri:Area/Main/Merge">001D87</idno><idno type="wicri:Area/Main/Curation">001D87</idno><idno type="wicri:Area/Main/Exploration">001D87</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Comparative efficacy of tocilizumab, abatacept and rituximab after non‐TNF inhibitor failure: results from a multicentre study</title><author><name sortKey="Pascart, Tristan" sort="Pascart, Tristan" uniqKey="Pascart T" first="Tristan" last="Pascart">Tristan Pascart</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Saint‐Philibert Hospital, Lille University, Lomme</wicri:regionArea><wicri:noRegion>Lomme</wicri:noRegion><wicri:noRegion>Lomme</wicri:noRegion></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, CHU Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>EA 4490, University‐Hospital of Lille, CHU Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Niger</country></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Niger</country></affiliation></author><author><name sortKey="Philippe, Peggy" sort="Philippe, Peggy" uniqKey="Philippe P" first="Peggy" last="Philippe">Peggy Philippe</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, CHU Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Drumez, Elodie" sort="Drumez, Elodie" uniqKey="Drumez E" first="Elodie" last="Drumez">Elodie Drumez</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Biostatistics, Univ. Lille, CHU Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Deprez, Xavier" sort="Deprez, Xavier" uniqKey="Deprez X" first="Xavier" last="Deprez">Xavier Deprez</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Valenciennes Hospital, Valenciennes</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Valenciennes</settlement></placeName></affiliation></author><author><name sortKey="Cortet, Bernard" sort="Cortet, Bernard" uniqKey="Cortet B" first="Bernard" last="Cortet">Bernard Cortet</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, CHU Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>EA 4490, University‐Hospital of Lille, CHU Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Duhamel, Alain" sort="Duhamel, Alain" uniqKey="Duhamel A" first="Alain" last="Duhamel">Alain Duhamel</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Biostatistics, Univ. Lille, CHU Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Houvenagel, Eric" sort="Houvenagel, Eric" uniqKey="Houvenagel E" first="Eric" last="Houvenagel">Eric Houvenagel</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Saint‐Philibert Hospital, Lille University, Lomme</wicri:regionArea><wicri:noRegion>Lomme</wicri:noRegion><wicri:noRegion>Lomme</wicri:noRegion></affiliation></author><author><name sortKey="Flipo, Rene Arc" sort="Flipo, Rene Arc" uniqKey="Flipo R" first="René-Marc" last="Flipo">René-Marc Flipo</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, CHU Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">International Journal of Rheumatic Diseases</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title><idno type="ISSN">1756-1841</idno><idno type="eISSN">1756-185X</idno><imprint><biblScope unit="vol">19</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1093">1093</biblScope><biblScope unit="page" to="1102">1102</biblScope><biblScope unit="page-count">10</biblScope><date type="published" when="2016-11">2016-11</date></imprint><idno type="ISSN">1756-1841</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1756-1841</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abatacept (adverse effects)</term><term>Abatacept (therapeutic use)</term><term>Aged</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antirheumatic Agents (adverse effects)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis, Rheumatoid (blood)</term><term>Arthritis, Rheumatoid (diagnosis)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Arthritis, Rheumatoid (immunology)</term><term>Biological Products (adverse effects)</term><term>Biological Products (therapeutic use)</term><term>Biomarkers (blood)</term><term>Blood Sedimentation</term><term>C-Reactive Protein (metabolism)</term><term>Drug Substitution</term><term>Female</term><term>France</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Rituximab (adverse effects)</term><term>Rituximab (therapeutic use)</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Failure</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Abatacept (effets indésirables)</term><term>Abatacept (usage thérapeutique)</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (effets indésirables)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antirhumatismaux (effets indésirables)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Facteurs temps</term><term>Femelle</term><term>France</term><term>Humains</term><term>Indice de gravité médicale</term><term>Marqueurs biologiques (sang)</term><term>Mâle</term><term>Polyarthrite rhumatoïde (diagnostic)</term><term>Polyarthrite rhumatoïde (immunologie)</term><term>Polyarthrite rhumatoïde (sang)</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Produits biologiques (effets indésirables)</term><term>Produits biologiques (usage thérapeutique)</term><term>Protéine C-réactive (métabolisme)</term><term>Rituximab (effets indésirables)</term><term>Rituximab (usage thérapeutique)</term><term>Substitution de médicament</term><term>Sujet âgé</term><term>Sédimentation du sang</term><term>Échec thérapeutique</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Abatacept</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Biological Products</term><term>Rituximab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>C-Reactive Protein</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Abatacept</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Biological Products</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Abatacept</term><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term><term>Produits biologiques</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Protéine C-réactive</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Marqueurs biologiques</term><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Abatacept</term><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term><term>Produits biologiques</term><term>Rituximab</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Blood Sedimentation</term><term>Drug Substitution</term><term>Female</term><term>France</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Failure</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Facteurs temps</term><term>Femelle</term><term>France</term><term>Humains</term><term>Indice de gravité médicale</term><term>Mâle</term><term>Substitution de médicament</term><term>Sujet âgé</term><term>Sédimentation du sang</term><term>Échec thérapeutique</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Aims: The aim of this study was to compare the efficacy of tocilizumab, rituximab and abatacept after a non‐tumor necrosis factor inhibitor (non‐TNFi) failure for the treatment of rheumatoid arthritis (RA). Materials and methods: This retrospective multi‐centre study included patients treated for RA with abatacept, rituximab or tocilizumab after having received in the previous line the first non‐TNFi. Data were collected from patient charts. The primary endpoint was the delta Disease Activity Index of 28 joints – erythrocyte sedimentation rate (DAS28‐ESR) and DAS28‐CRP (C‐reactive protein) at 12 months. The relative change in primary outcome measures from baseline were calculated. Results: One hundred patients started a second non‐TNFi between 2006 and 2013, including 15 patients treated with rituximab, 36 with tocilizumab and 49 with abatacept. The change of DAS28‐ESR was significantly different between the three groups (P = 0.001). In post hoc pairwise comparisons, patients treated with tocilizumab had a higher decrease of the DAS28‐ESR than patients treated by abatacept (median [interquartile range: IQR]: 36% [0; 54%] vs. 0% [0; 20%], P = 0.002). A similar non‐significant difference was found between tocilizumab and rituximab (median [IQR] decrease: 36% [0; 54%] vs. 0% [−11; 34%], P = 0.07). Similar results were found with the 12 months change in DAS28‐CRP. Conclusions: This study suggests a better efficacy of tocilizumab compared with abatacept and rituximab in situations of non‐TNFi failure.</div></front></TEI><affiliations><list><country><li>France</li><li>Niger</li></country><region><li>Hauts-de-France</li><li>Nord-Pas-de-Calais</li></region><settlement><li>Lille</li><li>Valenciennes</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Pascart, Tristan" sort="Pascart, Tristan" uniqKey="Pascart T" first="Tristan" last="Pascart">Tristan Pascart</name></noRegion><name sortKey="Cortet, Bernard" sort="Cortet, Bernard" uniqKey="Cortet B" first="Bernard" last="Cortet">Bernard Cortet</name><name sortKey="Cortet, Bernard" sort="Cortet, Bernard" uniqKey="Cortet B" first="Bernard" last="Cortet">Bernard Cortet</name><name sortKey="Deprez, Xavier" sort="Deprez, Xavier" uniqKey="Deprez X" first="Xavier" last="Deprez">Xavier Deprez</name><name sortKey="Drumez, Elodie" sort="Drumez, Elodie" uniqKey="Drumez E" first="Elodie" last="Drumez">Elodie Drumez</name><name sortKey="Duhamel, Alain" sort="Duhamel, Alain" uniqKey="Duhamel A" first="Alain" last="Duhamel">Alain Duhamel</name><name sortKey="Flipo, Rene Arc" sort="Flipo, Rene Arc" uniqKey="Flipo R" first="René-Marc" last="Flipo">René-Marc Flipo</name><name sortKey="Houvenagel, Eric" sort="Houvenagel, Eric" uniqKey="Houvenagel E" first="Eric" last="Houvenagel">Eric Houvenagel</name><name sortKey="Pascart, Tristan" sort="Pascart, Tristan" uniqKey="Pascart T" first="Tristan" last="Pascart">Tristan Pascart</name><name sortKey="Pascart, Tristan" sort="Pascart, Tristan" uniqKey="Pascart T" first="Tristan" last="Pascart">Tristan Pascart</name><name sortKey="Philippe, Peggy" sort="Philippe, Peggy" uniqKey="Philippe P" first="Peggy" last="Philippe">Peggy Philippe</name></country><country name="Niger"><noRegion><name sortKey="Pascart, Tristan" sort="Pascart, Tristan" uniqKey="Pascart T" first="Tristan" last="Pascart">Tristan Pascart</name></noRegion><name sortKey="Pascart, Tristan" sort="Pascart, Tristan" uniqKey="Pascart T" first="Tristan" last="Pascart">Tristan Pascart</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D87 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D87 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D3B23ACDCB126D11E04A087E0FB69A6B2A03E277
|texte= Comparative efficacy of tocilizumab, abatacept and rituximab after non‐TNF inhibitor failure: results from a multicentre study
}}
| This area was generated with Dilib version V0.6.34. |  |